There Is A Technique Called Selective Illumination. The Wall Street Journal Just Used It.

Accurate data in the wrong frame is more dangerous than a false argument.

By Dutch Rojas | RojasReport.com

---

There is a technique in advocacy journalism called Selective Illumination. Shine bright light on real numbers.
Leave the mechanism in the dark.
The audience concludes that the frame was built to produce.

---

The Wall Street Journal published a detailed examination of why American healthcare costs so much.

The data is real.
The sources are credible.
The charts are accurate.

And the picture it constructs is incomplete in ways that are not accidental.
This is an examination of Selective Illumination.

Shine a bright light on certain numbers. Leave others in the dark. The audience sees what you show them and draws the conclusions the frame was built to produce.

Here is what the article got right, what it omitted, and why the omissions matter more than the data.

WSJ: Why the US Spends So Much on Healthcare

---

What They Got Right

The consolidation map is accurate. According to the Health Care Affordability Lab at Yale, 21% of American hospitals now operate as monopolies in their markets. Another 30% operate in markets with higher concentration. That is not a functioning market. That is a protected oligopoly.

Administrative costs at 25% of total spend are sourced from a 2019 McKinsey and confirmed by David Cutler at Harvard. It is real. Billing complexity, claims processing, and prior authorization infrastructure are genuine cost drivers.

The inpatient procedure cost comparisons are real. A total hip replacement costs $29,000 in the United States versus $10,000 at peer nation. That gap is structural and documented.

The article is accurate about what it shows. The problem is what it chose not to show, and one critical thing it buried in a footnote, in text so small that most readers will never read it.

---

The Drug Pricing Section Contains A Devastating Admission Hidden In Fine Print

The drug price comparisons are striking. Herceptin costs $6,819 in the United States versus $1,360 in the UK. Enbrel at $6,238 versus $1,043 in Germany. Eliquis at $513 versus $96 in Spain.

These are list prices. And below the chart, in small footnote text, the article acknowledges: “Does not include all rebates.”

That footnote is the most important sentence in the entire piece.

Pharmacy Benefit Managers, Express Scripts, CVS Caremark, OptumRx, negotiate rebates from pharmaceutical manufacturers. Those rebates can represent 30-50% of the list price on branded medications. The spread between what the manufacturer receives and what appears on the chart is where billions in annual extraction occur.

The article correctly identifies that Americans pay more for drugs. It attributes this entirely to the government's negotiating posture; other governments force lower rates, the US government doesn’t. That is partially correct. What it does not mention: PBMs capture manufacturer rebates that do not consistently flow to patients at the pharmacy counter or reduce insurance premiums. They flow to the PBM.

The Journal acknowledged that the rebates exist. In a footnote. Then, they built an entire analytical section as if the footnote didn’t matter.

That is not an oversight. That is a choice about what the reader is meant to conclude.

---

This investigation is funded by physicians who decided the truth was worth paying for. Not a subscription. A decision. Join them at read.rojasreport.com.

---

The Physician Salary Comparison Is Methodologically Inconsistent

The article’s labor cost section states that American physicians make more than their counterparts in other countries and presents this as a cost driver.

The chart footnote, again in small text, reveals the methodology: “U.S. physician salaries are for general internal medicine physicians. Salaries for other countries’ physicians are for general practitioners.”

This is not a comparable data set.

General practitioners earn less than internal medicine physicians in every healthcare system worldwide. The article compared a higher-compensated US specialty against lower-compensated international equivalents and presented the result as a labor cost analysis. The US number at $245,000 is being compared against GP income in countries where that specialty earns less than the equivalent US specialty would.

A genuine comparison would use equivalent specialties. Or it would acknowledge the methodological limitation in the body of the article, not in footnote text after the conclusion has already been drawn by the reader.

Beyond the methodology, the comparison contains no structural context. US physicians graduate with an average of $250,000 in medical school debt at 6-7% interest. On a 10-year repayment schedule, that is approximately $33,000 annually in debt service before a single clinical hour is worked. UK physicians attend government-subsidized medical schools. Their debt burden at graduation is a fraction of that of their American counterparts.

US physicians, if independent, pay their own malpractice insurance, $20,000 to $150,000 annually, depending on specialty and geography. Their own health insurance. Their own practice overhead. None of this appears in the income comparison.

When you net physician income for debt service, malpractice, benefits, and overhead, the comparison to European counterparts looks substantially different than the headline chart suggests.

The article presented the headline as if it were the economic reality.

---

The Consolidation Section Names The Effect And Hides The Cause

The Journal correctly identifies that hospital consolidation has produced pricing power. Cities and communities dominated by single systems allow those systems to command higher rates from insurers. The map is accurate. The 21% monopoly figure is real.

What the article never explains is the mechanism that drove consolidation in the first place.

When a health system acquires an independent physician practice, the clinical reality does not change. The same physician sees the same patients. The same procedures are performed. The same outcomes are produced.

The billing entity changes.

Under a hospital tax ID, the same procedure is reimbursed at 200-300% of the independent practice rate. Medicare and private insurers pay dramatically more for the same work performed in a hospital outpatient department than in an independent physician's office. This differential is called the site-of-care payment differential. It is embedded in the Medicare fee schedule by design.

Health systems understood this arithmetic before the physicians they were acquiring did. The acquisition of an independent cardiology or orthopedic group is not primarily a clinical decision. It is a billing optimization. The system acquires the physician, converts the practice to a hospital outpatient department, and immediately captures 200-300% more reimbursement for identical services.

The share of physician-owned private practices fell from 53% in 2012 to 26% by 2022. Not because employed physicians provide better care. Because the fee schedule made acquisition more profitable than competition.

The consolidation map the Journal published is a consequence of this differential. The article shows the map. It never explains the mechanism that produced it. That is the most important missing sentence in the entire piece.

---

No one is coming to fund independent medicine journalism. So physicians are doing it themselves. 100,000+ strong. If this is worth something to you, put something behind it. read.rojasreport.com.

---

Administrative Costs: The Number Is Named. The Beneficiary Is Not.

Twenty-five percent of US healthcare spending is on administration. Billing, claims processing, customer service, and financial transactions. The article names the cost. It does not name who profits from the complexity that produces it.

Prior authorization exists as a constructed apparatus. Physician practices employ staff whose sole function is to request permission from insurers to provide care that has already been ordered. The insurer employs staff whose sole function is to deny, delay, or modify those requests. Neither population delivers a single unit of clinical care. Both are paid from the healthcare dollar.

The OIG found that a significant percentage of prior authorization denials in Medicare Advantage were subsequently reversed on appeal, meaning the care was appropriate, the denial was incorrect, and the delay was due to a product issue rather than a quality-control outcome.

UnitedHealth Group reported $370 billion in revenue in 2024. Its subsidiary Optum now employs more physicians than any other entity in the United States. UnitedHealth is simultaneously the insurer designing the prior authorization criteria, the PBM managing the drug formulary, and the employer of the physician submitting the authorization request.

The 25% administrative cost does not exist in the abstract. It exists inside organizations with names, shareholders, and quarterly earnings calls. The article names the cost. It does not name the organizations extracting it.

---

What The Article Did Not Cover At All

Certificate of Need laws. Forty states maintain regulations requiring government approval before new hospitals, surgery centers, or imaging facilities can be built. These laws were originally designed to prevent oversupply. In practice, they function as incumbent protection. Existing hospital systems are the primary participants in CON review hearings. They testify against new entrants. The monopoly map the Journal published did not appear by accident. It was built in part by regulations that existing systems lobbied to maintain. CON laws do not appear in this article.

Price transparency. Hospitals have been legally required to publish their negotiated rates since 2021. A functioning market requires prices. Healthcare has been deliberately kept opaque by the same systems that profit from that opacity. Compliance with transparency requirements has been incomplete. Enforcement has been weak. The article identifies high prices as the primary cost driver and never mentions that the legal requirement to make those prices visible has been systematically resisted. That resistance does not appear.

The nonprofit tax exemption. Large nonprofit hospital systems pay no federal income tax, no property tax in most jurisdictions, and no state income tax. The value of this exemption across the nonprofit hospital sector is estimated at $30-50 billion annually. In exchange, nonprofit status requires the provision of community benefit. Multiple peer-reviewed studies have found that the value of tax exemptions often exceeds the community benefits provided by large systems that report billions in operating surpluses. The implicit public subsidy that flows to nonprofit systems does not appear in this article.

Private equity extraction. KKR, Blackstone, Apollo, and their peers have deployed hundreds of billions of dollars into healthcare acquisitions. The private equity model follows a documented pattern: acquire, extract administrative cost reduction, load the entity with acquisition debt, increase volume through aggressive billing, and exit within five to seven years. The communities left holding facilities weakened by debt and extraction cycles are not represented in the return calculation. Private equity’s role in healthcare cost inflation has been documented in peer-reviewed literature. It does not appear here.

340B pharmaceutical program capture. The 340B program was designed to allow safety-net hospitals serving low-income populations to purchase drugs at significantly reduced prices. The savings were intended to cross-subsidize care for the underserved. The program has expanded dramatically to include large nonprofit health systems that do not primarily serve low-income populations. The program’s capture by large systems does not appear in this article.

---

The systems this reporting exposes have million-dollar communications budgets. This publication has readers who give a damn. If that matters to you, fund it. read.rojasreport.com.

---

The Utilization Argument Inverts The Causation

The article presents rising healthcare utilization as a cost driver and correctly notes that GLP-1 drugs for weight loss have increased spending. Both observations are accurate.

The causation runs in the other direction.

Utilization distortion is a predictable consequence of price opacity and misaligned incentives. When patients cannot see prices, they cannot make rational decisions. When physicians practice in systems with volume-based revenue incentives, clinical decisions are made inside a financial context that the article never examines. When insurers design benefit structures that make high-cost system-owned facilities appear equivalent to lower-cost independent facilities, patients consume more expensive care without knowing it.

Blaming utilization without addressing the opacity and incentive structures that produce it is the equivalent of blaming traffic without mentioning that the road was designed with no exits.

A functioning market self-regulates utilization through price signals. Healthcare has been deliberately kept opaque. The article identified the symptom and omitted the cause.

---

One Final Observation

The article ends with a disclosure: “This explanatory article may be periodically updated.”

A living document with no correction log.
Claims can be quietly revised.
Context can be silently added.
The initial frame, the one most readers will absorb and remember, has already done its work.

---

The Conclusion: The Article Does Not Reach

American healthcare costs too much.
On this, the article and I agree completely.

The causes it identifies, consolidation, administrative overhead, drug pricing, physician compensation, and utilization, are real factors. None of them are invented.

The picture constructed from those factors is incomplete.

The facility fee differential that drove consolidation is absent.
The PBM apparatus used to extract drug pricing margins is acknowledged in a footnote but never explained.

The nonprofit tax subsidy is invisible.
CON law incumbent protection is not mentioned.
Private equity extraction is not examined.
Price transparency resistance is not named. 340B capture does not appear.

The physician salary comparison uses different specialties across countries, and that fact is buried in a footnote after the conclusion is drawn.

The result is an article that is accurate about what it shows and strategic about what it hides. The audience finishes reading knowing that healthcare costs too much and believing that physician compensation, drug company behavior, and patient utilization are the primary causes.

The systems that actually determine the cost and benefit from the audience believing something else do not appear.

There is a name for this technique.

Selective Illumination.

It is more dangerous than a false argument because it cannot be refuted by fact-checking. Every number in the article is accurate.

What is missing cannot be found by reading it more carefully.

It can only be found by asking what was never there.

---

-Rojas out.

---

GLOSSARY

Selective Illumination: The technique of presenting accurate data within a frame that produces a predetermined conclusion by omitting structural context. Cannot be refuted by fact-checking because the individual facts are true.

Site-of-Care Payment Differential: Medicare and commercial insurers pay higher rates for the same procedure when it is billed under a hospital tax ID rather than a physician’s independent practice. Same physician. Same patient. Same procedure. Different billing entity. Different reimbursement.

Pharmacy Benefit Manager (PBM): The intermediary that manages drug benefits on behalf of insurers. Negotiates rebates from drug manufacturers. The spread between the list price and the net price after rebates is where significant margin is extracted.

Certificate of Need (CON) Law: State regulations requiring government approval before new healthcare facilities can be built or expanded. Existing systems participate in CON hearings. The practical effect is incumbent protection.

340B Program: Federal program allowing certain hospitals to purchase outpatient drugs at significantly reduced prices. Originally designed for safety-net hospitals. Expanded to include large nonprofit systems that do not primarily serve low-income populations.

Prior Authorization: The process by which a physician must obtain insurer approval before providing care that has already been ordered. The OIG found that a significant percentage of Medicare Advantage denials were subsequently reversed on appeal — meaning the care was appropriate and the delay was the outcome, not a quality control measure.